Pathology of rituximab-induced Kaposi sarcoma flare

BMC Clinical Pathology

Volumn 8, Issue 1, 2008, Pages

  Pantanowitz, Liron ^a   Früh, Klaus ^b   Marconi, Sharon ^a   Moses, Ashlee V ^b   Dezube, Bruce J ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD20 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DOXORUBICIN; GENE PRODUCT; K5 GENE; LNA 1 GENE; PREDNISONE; RITUXIMAB; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; MALE; PHYSICAL EXAMINATION; RASH; T LYMPHOCYTE;

EID: 49649126380     PISSN: 14726890     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-8-7     Document Type: Article

References (22)

1. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. S Ishido C Wang BS Lee GB Cohen JU Jung, J Virol 2000 74 5300 9 10799607 10.1128/JVI.74.11.5300- 5309.2000
2. Kaposi's sarcoma-associated herpesvirus immediate early gene activity. V Lacoste C de la Fuente F Kashanchi A Pumfery, Front Biosci 2004 9 2245 72 10.2741/1394 15353285
3. Kaposi's sarcoma: a model of both malignancy and chronic inflammation. JL Douglas JK Gustin B Dezube JL Pantanowitz AV Moses, Panminerva Med 2007 49 119 38 17912148
4. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). PS Gill C Loureiro M Bernstein-Singer MU Rarick F Sattler AM Levine, Ann Intern Med 1989 110 937 40 2719427
5. Iatrogenic Kaposi's sarcoma following steroid therapy for nonspecific interstitial pneumonia with HHV-8 genotyping. M Joo S Soon Lee H Jin Park HS Shin, Pathol Res Pract 2006 202 113 7 10.1016/j.prp.2005.11.005 16413694
6. Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS. S Jinno C Goshima, AIDS Read 2008 18 2 102 104
7. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. M Bower M Nelson AM Young C Thirlwell T Newsom-Davis S Mandalia T Dhillon P Holmes BG Gazzard J Stebbing, J Clin Oncol 2005 23 5224 5228 10.1200/JCO.2005.14.597 16051964
8. Kaposi sarcoma flares during effective antiretroviral treatment. DM Aboulafia, AIDS Read 2005 15 190 1 15844240
9. Recrudescent Kaposi's sarcoma after initiation of HAART: A manifestation of immune reconstitution syndrome. RS Leidner DM Aboulafia, AIDS Patient Care and STDs 2005 19 635 44 10.1089/apc.2005.19.635
10. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. A Casquero A Barroso ML Fernández Guerrero M Górgolas, Ann Hematol 2006 85 185 7 10.1007/s00277-005-0038-4 16341862
11. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. L Gérard A Bérezné L Galicier V Meignin M Obadia N De Castro C Jacomet R Verdon I Madelaine-Chambrin E Boulanger S Chevret F Agbalika E Oksenhendler, J Clin Oncol 2007 25 3350 6 10.1200/JCO.2007.10.6732 17664482
12. Progression of classic Kaposi's sarcoma with rituximab. KS Clifford MF Demierre, J Am Acad Dermatol 2005 53 155 7 10.1016/j.jaad.2004.12.048 15965441
13. Brief communication: rituximab in HIV-associated multicentric Castleman disease. M Bower T Powles S Williams TN Davis M Atkins S Montoto C Orkin A Webb M Fisher M Nelson B Gazzard J Stebbing P Kelleher, Ann Intern Med 2007 147 836 9 18087054
14. Rituximab therapy for HIV-associated Castleman disease. AG Marcelin L Aaron C Mateus E Gyan I Gorin JP Viard V Calvez N Dupin, Blood 2003 102 2786 8 10.1182/blood-2003-03-0951 12842986
15. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. S Neuville F Agbalika C Rabian J Brière JM Molina, Am J Hematol 2005 79 337 9 10.1002/ajh.20418 16044438
16. Immunohistological evaluation of immune cell infiltrate in cutaneous Kaposi's sarcoma. MR Husein, Cell Biol Int 2008 32 157 62 10.1016/j.cellbi.2007. 08.021 17950633
17. Langerhans' cells and lymphocytic infiltrate in AIDS-associated Kaposi's sarcoma. An immunohistochemical study. F Valcuende-Cavero MI Febrer-Bosch A Castells-Rodellas, Acta Derm Venereol 1994 74 183 7 7521102
18. Association of clinical progression in classic Kaposi's sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers. AJ Stratigos D Malanos G Touloumi A Antoniou I Potouridou D Polydorou AD Katsambas D Whitby N Mueller JD Stratigos A Hatzakis, Arch Dermatol 2005 141 1421 6 10.1001/archderm.141.11.1421 16301389
19. Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma. J Stebbing B Gazzard T Newsom-Davis M Nelson S Patterson F Gotch S Mandalia M Bower, Int J Cancer 2004 108 473 4 10.1002/ijc.11601 14648716
20. A review of rituximab in cutaneous medicine. N Scheinfeld, Dermatol Online J 2006 12 3 16638371
21. Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus. C Tomescu WK Law DH Kedes, J Virol 2003 77 9669 84 12915579 10.1128/JVI.77.17.9669-9684.2003
22. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. C Casper EM Krantz L Corey SR Kuntz J Wang S Selke S Hamilton ML Huang A Wald, J Infect Dis 2008 198 23 30 10.1086/588820 18491970